Shares of Novo Nordisk and Eli Lilly added to the fall after Mass Eye and Ear, a Harvard-affiliated hospital, revealed in a new study published in the journal JAMA Ophthalmology that people prescribed semaglutide, sold as Ozempic and Wegovy (Novo ), have a high risk. of developing a “potentially blinding eye condition” called non-arteritic anterior ischemic optic neuropathy (NAION).
“The study found that people with diabetes who were given semaglutide by their doctor and then filled the prescription were more than four times more likely to be diagnosed with NAION,” Mass Eye and Ear wrote in a news release. and added: “Those who were overweight or obese and prescribed this drug were more than seven times more likely to get the diagnosis.”
The study, which was led by Joseph Rizzo, MD, director of the Neuro-Ophthalmology Service at Mass Eye and Ear, wrote that “the use of these drugs has exploded in industrialized countries and they have provided very significant benefits of many ways, but future discussions between a patient and their doctor should include NAION as a potential risk.”
English 
Español de Venezuela 